Turkish Abstract Abstract Free Full Text English Similar Articles Mail to Author

¹Udayana University, Medical Program, Faculty of Medicine, Bali, Indonezya
²Udayana University, Department of Ophthalmology, Faculty of Medicine, Bali, Indonezya DOI : 10.37845/ret.vit.2024.33.48 Diabetic retinopathy is one of the complications of diabetes mellitus and causes visual disturbances. This increasing number of diabetic retinopathies needs to be addressed because it can affect various aspects of life. The current management of diabetic retinopathy still has limitations in terms of the therapeutic effect and the potential for permanent vision loss. The development of research shows that injection of recombinant adeno-associated virus (rAAV) with sFlt-1 linkage and recombinant plasminogen activator (rTPA) has the potential to be used as an alternative treatment for diabetic retinopathy. This literature review aims to collect and analyze various sources regarding the potential of the combination of rAAV sFLT-1 and rTPA as a treatment for diabetic retinopathy. This literature review was compiled systematically by synthesizing literature from search engines ScienceDirect, PubMed, and Research Gate. This modality was administered by injecting a combination of rAAV sFLT-1 and rTPA subretinally once. The results of the literature analysis show that rAAV sFLT-1 will trigger the body?s immune response against adenovirus and recombinant particles carried, while rTPA will inhibit angiogenesis that occurs in diabetic retinopathy. This modality can improve and maintain visual acuity in diabetic retinopathy patients with minimal side effects. The combination injection of rAAV sFLT-1 and rTPA is an appropriate treatment modality for diabetic retinopathy in terms of effects and adherence. Keywords : Diabetic retinopathy, Recombinant tissue plasminogen activator, Vector delivered-endogenous anti-VEGF